Allan J. Hovan

Allan J. Hovan

Auto-generated profile, based on publicly available information

Allan J. Hovan

Department of Oral Oncology and Dentistry, British Columbia Cancer, Vancouver, Canada

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2018 in JMIR Research Protocols
Verified
Journal Article
Open access
MBMichael T. Brennan
Michael T. Brennan
BHBengt Hasséus
Bengt Hasséus
AHAllan J Hovan
Allan J Hovan
Judith Evelyn Raber-DurlacherJudith Evelyn Raber-Durlacher
Judith Evelyn Raber-Durlacher
NBNicole Blijlevens
Nicole Blijlevens
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
The oral cavity is a common site of complications related to the cytotoxic effect of high-dose chemotherapy and radiation therapy. Considering our limited understanding of the burden of illness in the oral cavity from various cytotoxic therapies, it is difficult to produce evidence-based, preventive and management protocols. A prospective multicenter study is necessary to collect data on the burden of illness from various cytotoxic regimens. The objectives of this prospective international observational multicenter study in hematopoietic stem cell transplant (HSCT) patients are to establish the nature, incidence and temporal relationship of oral complications related to conditioning regimens (chemotherapy with or without total body irradiation), stem cell transplantation and the immunologic reactions (mainly graft-vs-host-disease) that may follow, and to determine what subjective and objective oral complications related to treatment can predict negative clinical and economic outcomes and reduced quality of life. Adult patients at six study sites receiving full intensity conditioning, reduced intensity conditioning or nonmyeloablative conditioning, followed by autologous or allogeneic hematopoietic stem cell infusion, are included. A pre-treatment assessment includes medical conditions, planned chemo- and radiation therapy regimen, medications, allergies, social history, patient report of oral problems, dental history, subjective oral complaints, objective measures of oral conditions, current laboratory values, dental treatment recommended and untreated dental disease. Starting 1-3 days after hematopoietic stem cell infusion, a bedside assessment is completed 3 days per week until resolution of neutropenia. A patient questionnaire is also completed during hospitalization. Beyond this time, patients with continued oral mucositis or other oral problems are followed 1 day per week in an inpatient or outpatient setting. Additional visits for urgent care for acute oral problems after hospitalization are documented. Autologous transplant patients are being followed up at 100 days (SD 30 days) and at 1 year (SD 30 days) post-transplantation to identify any long-term side effects. Patients treated with allogeneic transplantation are being followed at 100 days (SD 30 days), 6 months (SD 30 days), and 12 months (SD 30 days). The follow-up assessments include cancer response to therapy, current medical conditions, medications, subjective and objective oral findings, quality of life measures and laboratory values. The targeted enrollment is 254 patients who have received HSCT. A total of 260 participants have been enrolled, with 233 (91%) who have received HSCT. We anticipate enrollment of 20-30 additional participants to obtain the sample size of 254 enrolled participants who have received HSCT. The results of the ongoing prospective study will provide a unique dataset to understand the impact of oral complications on patients undergoing HSCT and provide needed evidence for guidelines regarding the management of this patient cohort.

3 June 2026 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
AHAllan J. Hovan
Allan J. Hovan
MBMichael T. Brennan
Michael T. Brennan
BHBengt Hasséus
Bengt Hasséus
Judith Evelyn Raber-DurlacherJudith Evelyn Raber-Durlacher
Judith Evelyn Raber-Durlacher
MHMarie-Charlotte Huysmans
Marie-Charlotte Huysmans
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
Purpose: The aims of this investigation within the Orastem study were to describe the prevalence of subjective taste change, levels of patient-reported distress associated with taste change, and factors predicting taste change after hematopoietic cell transplantation (HCT) with a particular focus on factors predictive of severe and/or persistent (present at 12 months) taste change. Methods: Altogether, 238 patients at five cancer centers were followed during HCT hospitalization and up to 12 months post-HCT. Patients with taste change were compared to non-affected patients with respect to gender, age, transplant type, previous chemotherapy, conditioning regimen(s), oral mucositis, pre-HCT salivary flow, oral hygiene status and, in allogeneic HCT recipients, chronic oral graft-versus-host disease (GVHD). Distress from taste change was also evaluated. Results: During hospitalization, taste change was reported by over one-third (81/238) of patients to an open question on oral symptoms; of these, 41% reported taste change as their worst/most bothersome oral symptom. To a specific question on distress due to taste change, 76% of all patients reported some level of distress. Taste change from previous chemotherapy and full intensity conditioning were risk factors for severe taste change during hospitalization. At three months, allogeneic transplant patients reported a higher rate of severe taste change compared to autologous transplant patients. Increased age predicted severe taste change at 6 and 12-month follow-up. At twelve months, 13.1% of patients reported distress from taste change. Conclusion: This study confirmed taste change as a common clinical complaint post-HCT. Taste change remained a significant issue for a small subset of patients at 12 months. Further research is required to develop effective preventive and management strategies for this common oral side-effect post-HCT.

18 September 2025 in Oral Diseases
Verified
Journal Article
Open access
KSKristina Skallsjö
Kristina Skallsjö
MBMichael T. Brennan
Michael T. Brennan
BHBengt Hasséus
Bengt Hasséus
JÖJenny Öhman
Jenny Öhman
Judith Evelyn Raber-DurlacherJudith Evelyn Raber-Durlacher
Judith Evelyn Raber-Durlacher
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
Objective: Oral complications may negatively influence outcomes of haematopoietic cell transplantation (HCT). A comprehensive view of oral symptoms and symptom burden post‐HCT is lacking. This study aimed to determine the prevalence, severity, and temporal relationships of oral symptoms and their impact on well‐being in the early post‐HCT phase. Effects of transplant type and conditioning intensity were evaluated. Methods: In this prospective multicentre observational study, adult HCT recipients were interviewed and completed questionnaires on oral symptoms and well‐being three times a week during hospitalisation early post‐HCT. Results: Of 194 patients, 177 (91.2%) reported oral symptoms. Dry mouth was the earliest and most common (80.9%) followed by oral pain (35.6%), thickening/swollen mucosa (33.0%), and taste changes (30.9%). Symptom frequency peaked on days 6 to 11 post‐HCT and caused significant burden: 59.3% experienced moderate to severe distress and 53.6% reported moderate to severe impact on well‐being. Symptom prevalence was highest among patients who received allogeneic HCT with MAC and those who underwent autologous HCT. Overall, MAC regimens were associated with earlier and more frequent symptoms, greater distress and higher impact on well‐being during days 0 to 11 post‐HCT compared to reduced/non‐myeloablative regimens. Conclusions: Oral symptoms are prevalent, burdensome and significantly impact well‐being early post‐HCT, underscoring the need for close monitoring and supportive oral care.

15 September 2017 in JMIR Preprints
Verified
Preprint
Open access
MBMichael T. Brennan
Michael T. Brennan
BHBengt Hasséus
Bengt Hasséus
AHAllan J Hovan
Allan J Hovan
Judith Evelyn Raber-DurlacherJudith Evelyn Raber-Durlacher
Judith Evelyn Raber-Durlacher
NBNicole Blijlevens
Nicole Blijlevens
IBInger von Bültzingslöwen
Inger von Bültzingslöwen
BACKGROUND The oral cavity is a common site of complications related to the cytotoxic effect of high-dose chemotherapy and radiation therapy. Considering our limited understanding of the burden of illness in the oral cavity from various cytotoxic therapies, it is difficult to produce evidence-based, preventive and management protocols. A prospective multicenter study is necessary to collect data on the burden of illness from various cytotoxic regimens. OBJECTIVE The objectives of this prospective international observational multicenter study in hematopoietic stem cell transplant (HSCT) patients are to establish the nature, incidence and temporal relationship of oral complications related to conditioning regimens (chemotherapy with or without total body irradiation), stem cell transplantation and the immunologic reactions (mainly graft-vs-host-disease) that may follow, and to determine what subjective and objective oral complications related to treatment can predict negative clinical and economic outcomes and reduced quality of life. METHODS Adult patients at six study sites receiving full intensity conditioning, reduced intensity conditioning or nonmyeloablative conditioning, followed by autologous or allogeneic hematopoietic stem cell infusion, are included. A pre-treatment assessment includes medical conditions, planned chemo- and radiation therapy regimen, medications, allergies, social history, patient report of oral problems, dental history, subjective oral complaints, objective measures of oral conditions, current laboratory values, dental treatment recommended and untreated dental disease. Starting 1-3 days after hematopoietic stem cell infusion, a bedside assessment is completed 3 days per week until resolution of neutropenia. A patient questionnaire is also completed during hospitalization. Beyond this time, patients with continued oral mucositis or other oral problems are followed 1 day per week in an inpatient or outpatient setting. Additional visits for urgent care for acute oral problems after hospitalization are documented. Autologous transplant patients are being followed up at 100 days (SD 30 days) and at 1 year (SD 30 days) post-transplantation to identify any long-term side effects. Patients treated with allogeneic transplantation are being followed at 100 days (SD 30 days), 6 months (SD 30 days), and 12 months (SD 30 days). The follow-up assessments include cancer response to therapy, current medical conditions, medications, subjective and objective oral findings, quality of life measures and laboratory values. The targeted enrollment is 254 patients who have received HSCT. RESULTS A total of 260 participants have been enrolled, with 233 (91%) who have received HSCT. We anticipate enrollment of 20-30 additional participants to obtain the sample size of 254 enrolled participants who have received HSCT. CONCLUSIONS The results of the ongoing prospective study will provide a unique dataset to understand the impact of oral complications on patients undergoing HSCT and provide needed evidence for guidelines regarding the management of this patient cohort.